About this iReport
  • Not verified by CNN

  • Click to view YourLegal's profile
    Posted July 24, 2014 by
    Vandalia, Ohio

    More from YourLegal

    Xarelto Bleeding Lawsuit Alleges Xarelto Was The Cause Of Serious ANd Uncontrolled Bleeding


    Court records show that the Kentucky woman’s Xarelto bleeding lawsuit against Janssen Research & Development and Bayer Corp. alleges that she was prescribed the blood thinner in July 2012 to treat atrial fibrillation. In February 2013, she suffered severe internal and gastrointestinal bleeding that required hospitalization in order for doctors to stop the bleeding. The Xarelto bleeding complaint further alleges that the defendants were negligent in introducing the drug. (Stuntebeck v. Janssen Research & Development LLC et al, Case Number 140201754) The Xarelto complaint was filed a month after the Pennsylvania Supreme Court’s January 21st ruling that pharmaceutical companies in Pennsylvania can be held negligent for marketing or designing drugs that they know or should have known are to dangerous to use.


    The blood thinning medication Xarelto®, which is marketed by Johnson & Johnson's Janssen Pharmaceuticals division and manufactured by Bayer, was approved by the Food and Drug Administration (FDA) in July 2011 for use in patients with atrial fibrillation (AF) to reduce the risk of stroke or who recently underwent hip or knee replacement surgery to reduce the risk of blood clots and recently expanded its use for the general treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE).


    According to the Xarelto bleeding lawsuit filed, the anticoagulant drug Xarelto (rivaroxaban) is alleged to cause serious and uncontrolled internal bleeding that might be irreversible due to no known antidote to counteract it, that could result in life-threatening injuries and even death.


    Adverse events associated with the use of Xarelto are on the rise reports the Institute for Safe Medicine Practices (ISMP). According to recent data from the U.S. Food & Drug Administration (FDA), the agency received a total of 680 Xarelto adverse event reports in the first quarter of 2013. These recent reports have Xarelto complaints out pacing complications from Pradaxa for the first time, another blood thinner in the same class, according to the ISMP.


    **ismp.org/quarterwatch/pdfs/2013Q1.pdf, Institute for Safe Medication Practices, May 7, 2014.



    Add your Story Add your Story